Richard C. Kevin
TitleCited byYear
Pharmacology of indole and indazole synthetic cannabinoid designer drugs ab-fubinaca, adb-fubinaca, ab-pinaca, adb-pinaca, 5f-ab-pinaca, 5f-adb-pinaca, adbica, and 5f-adbica
SD Banister, M Moir, J Stuart, RC Kevin, KE Wood, M Longworth, ...
ACS chemical neuroscience 6 (9), 1546-1559, 2015
982015
Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135
SD Banister, J Stuart, RC Kevin, A Edington, M Longworth, SM Wilkinson, ...
ACS chemical neuroscience 6 (8), 1445-1458, 2015
922015
Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3, 4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor
L Ramos, C Hicks, R Kevin, A Caminer, R Narlawar, M Kassiou, ...
Neuropsychopharmacology 38 (11), 2249, 2013
892013
Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, andá…
SD Banister, M Longworth, R Kevin, S Sachdev, M Santiago, J Stuart, ...
ACS chemical neuroscience 7 (9), 1241-1254, 2016
862016
Structure–activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues
SD Banister, J Stuart, T Conroy, M Longworth, M Manohar, C Beinat, ...
Forensic Toxicology 33 (2), 355-366, 2015
262015
Defensive aggregation (huddling) in Rattus norvegicus toward predator odor: individual differences, social buffering effects and neural correlates
MT Bowen, RC Kevin, M May, LG Staples, GE Hunt, IS McGregor
PLoS One 8 (7), e68483, 2013
232013
In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA
RC Kevin, TW Lefever, RW Snyder, PR Patel, TR Fennel, JL Wiley, ...
Forensic Toxicology, 2017
222017
Thermolytic degradation of synthetic cannabinoids: chemical exposures and pharmacological consequences
BF Thomas, TW Lefever, RA Cortes, AL Kovach, AO Cox, PR Patel, ...
J Pharmacol Exp Ther, 2017
202017
Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-fluoro-CUMYL-PICA
TF Gamage, CE Farquhar, TW Lefever, JA Marusich, RC Kevin, ...
The Journal of Pharmacology and Experimental Therapeutics, 2018
192018
Pharmacology of cumyl-carboxamide synthetic cannabinoid new psychoactive substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and their analogues
M Longworth, SD Banister, R Boyd, RC Kevin, M Connor, IS McGregor, ...
ACS chemical neuroscience 8 (10), 2159-2167, 2017
172017
Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA
RC Kevin, KE Wood, J Stuart, AJ Mitchell, M Moir, SD Banister, M Kassiou, ...
Journal of Psychopharmacology, 2017
132017
Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice
TW Lefever, JA Marusich, BF Thomas, DG Barrus, NC Peiper, RC Kevin, ...
Substance Abuse: Research and Treatment, 2017
122017
Composition and use of cannabis extracts for childhood epilepsy in the Australian community
A Suraev, N Lintzeris, J Stuart, RC Kevin, R Blackburn, E Richards, ...
Scientific reports 8 (1), 10154, 2018
82018
Urinary cannabinoid levels during nabiximols (Sativex«)-medicated inpatient cannabis withdrawal
RC Kevin, DJ Allsop, N Lintzeris, AJ Dunlop, J Booth, IS McGregor
Forensic Toxicology 35 (1), 33-44, 2017
82017
Synthesis and pharmacology of new psychoactive substance 5F‐CUMYL‐P7AICA, a scaffold‐hopping analog of synthetic cannabinoid receptor agonists 5F‐CUMYL‐PICA and 5F‐CUMYL‐PINACA
SD Banister, A Adams, RC Kevin, C Macdonald, M Glass, R Boyd, ...
Drug testing and analysis 11 (2), 279-291, 2019
52019
Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA
RC Kevin, AL Kovach, TW Lefever, TF Gamage, JL Wiley, IS McGregor, ...
5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposureá…, 2019
5*2019
Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN‐18
RC Kevin, TW Lefever, RW Snyder, PR Patel, TF Gamage, TR Fennell, ...
Drug testing and analysis 10 (1), 137-147, 2018
42018
Synthetic cannabinoid hydroxypentyl metabolites retain efficacy at human cannabinoid receptors
TF Gamage, CE Farquhar, RJ McKinnie, RC Kevin, IS McGregor, ...
Journal of Pharmacology and Experimental Therapeutics 368 (3), 414-422, 2019
32019
The chemistry and pharmacology of synthetic cannabinoid SDB‐006 and its regioisomeric fluorinated and methoxylated analogs
SD Banister, A Olson, M Winchester, J Stuart, AR Edington, RC Kevin, ...
Drug testing and analysis 10 (7), 1099-1109, 2018
32018
The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F‐PY‐PICA, 5F‐PY‐PINACA, and their analogs
SD Banister, RC Kevin, L Martin, A Adams, C Macdonald, JJ Manning, ...
Drug testing and analysis, 2019
22019
The system can't perform the operation now. Try again later.
Articles 1–20